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Chemical screening profiles on blood specimens
are designed to yield information that may lead to
new and additional clinical diagnoses, to revision of
clinically established diagnoses, to confirmed impressions of the physician and to following the course of
diseases during a patient's hospitalization. Screening
profiles on blood are designed to indicate diseases of
the liver, kidney, heart, striated muscle and other
organs; they may be helpful in the diagnosis of
anemia, diabetes mellitus, gout, congestive heart
failure, osteomalacia and hyperlipidemia, hyperparathyroidism and other diseases. When these screening
profiles were first introduced, there was widespread
skepticism among physicians as to their value and
their yield and some skepticism remains as to the
usefulness of a broad spectrum of laboratory tests.
The relative number of new clinical diagnoses
generated from blood chemistry screening profiles
has been reported in five studies of three different
patient populations: hospital patients, hospital clinic
patients and patients presenting to doctors' offices
(Table 1). The percentage of new diagnoses ranged
from 3-16.9% with the percentage tending to increase with the number and selection of tests. New
clinical diagnoses were obtained in 4% and 8.3%
of hospital patients, 3 % of hospital clinic patients,
and 5.5% and 16.9% of patients presenting to doctors' offices. The blood chemistries that were most
frequently abnormal were glucose, bilirubin, alkaline
phosphatase, serum glutamic oxalacetic transaminase
(SGOT), lactic dehydrogenase (LDH), uric acid,
cholesterol, creatinine, urea nitrogen and hemo-
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globin; the diagnoses that were suggested and subsequently confirmed by the abnormal blood chemistries are given in Table 2. Diagnoses other than
those listed in this table were generated but at a
lower frequency.
Occasionally, elevated calcium led to a diagnosis of primary hyperparathyroidism and an elevated protein led to a diagnosis of multiple myeloma.
If these blood screening profiles had uniformly included other blood tests, such as iron and iron binding capacity for anemia, triglycerides for hyperlipoproteinemia and protein bound iodine (PBI) or
thyroxine (T-4) for thyroid disease, then the percentage of patients yielding new diagnoses would
have increased. It must be emphasized that the initial
chemical screening tests in themselves did not usually
lead directly to the assigned diagnosis but more
definitive tests were required.
Table 2 indicates the laboratory screening
values that generated new clinical diagnoses and in
most instances, required a change in treatment. Thus,
the screening tests contributed to the recognition of
otherwise unsuspected disease. The abnormal test
results may be of value in arriving at earlier diagnoses, earlier treatment and reduction of time for
subsequent investigation since the results are available sooner than under previous conditions where
laboratory tests were ordered individually. If clinical
features alone were used to guide the physician in
ordering laboratory tests, abnormal test values would
be obtained in less than 1.5 % of the patients ( 4) .
Selection of the most appropriate tests for chemical
screening is still not complete since different populations of patients may require different groupings of
chemical screening tests.
MCV QUARTERLY 9(4): 360-361, 1973
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TABLE 1
N EW DIAGNOSES OBTAINED BY CHEMICAL SCREENING PROFILES
ON BLOOD IN DIFFERENT PATIENT POPULATIONS
Patient Population

Percent of Patients Yielding New
Diagnoses

Hospital Patients

4.0
8. 3
Hospital Clinic Patients 3. 0
5.5
Patients Presenting to
16. 9
Doctors' Offices

(Belliveau et al., 1970)
(Carmalt et al., 1970)
(Young and Drake, 1966)
(Percy-Robb et al., 1971)
(Carmalt et al. , 1970)

ABNORMAL BLOOD CHEMISTRIES BY CHEMICAL SCREENING
PROFILES AND FREQUENTLY FOUND NEW DIAGNOSES

Glucose
Bilirubin
Alkaline Phosphatase
Serum Glutamic Oxalacetic
Transaminase (SGOT)
Lactic Dehydrogenase (LDH)
Uric Acid
Cholesterol

Creatinine
Urea Nitrogen
Hemoglobin

Data are not included on abnormal laboratory
values that tended to confirm the impressions of the
physician based on his history and physical examination of the patient. These profiles also contribute to
patient care by providing indicated laboratory tests
rapidly and efficiently (3). These profiles also help
to detect organ systems that may be functioning
normally and thus, may not require a doctor's attention. If these data were available, then the value of
chemical screening profiles would be even more
apparent.
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